article thumbnail

The Big Three PBMs’ 2025 Formulary Exclusions: Humira, Stelara, Private Labels, and the Shaky Future for Pharmacy Biosimilars (rerun)

Drug Channels

This week, Im rerunning some popular posts while I prepare for Fridays live video webinar: PBM Industry Update: Trends, Challenges, and Whats Ahead. As youll see below, the combination of formulary exclusion and private labels is creating an increasingly confusing and crowded biosimilar marketplace.

article thumbnail

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels

This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. During Friday's webinar, Ill share some updated thoughts on biosimilars and PBMs private label products. Click here to see the original post.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UCB reports success in phase 3 study of fenfluramine for CDD

Pharma Times

The company is also running an open-label, long-term extension to evaluate safety and tolerability over 52 weeks. UCB noted that fenfluramine was generally well-tolerated in this study, aligning with its established safety profile in previous trials focused on Dravet and Lennox-Gastaut syndromes.

Diabetes 128
article thumbnail

Pharma Email Marketing Solutions for Large Lists

Pharma Marketing Network

Missteps in off-label promotion or data security can trigger legal and reputational risks. Large pharma email marketing programs often pull from multiple databases: CRM records, rep interactions, webinar registrants, and more. For starters, every email must comply with HIPAA, CAN-SPAM, and FDA regulations. API integration also matters.

HIPAA 52
article thumbnail

What are the Top Pharma Podcasts in 2025?

Pharma Marketing Network

Many leaders now prefer podcasts over webinars or whitepapers for staying informed. FDA Frontlines” A reliable resource for regulatory professionals, FDA Frontlines keeps tabs on advisory committee decisions, label expansions, and safety communications. Another reason for their rise is the growing need for real-time updates.

article thumbnail

PBM Industry Update: Trends, Challenges, and What's Ahead (NEW Live Video Webinar)

Drug Channels

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: PBM Industry Update: Trends, Challenges, and What's Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. This event is part of The Drug Channels 2025 Video Webinar Series.

article thumbnail

Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression

Pharma Times

Eligible participants may enter an open-label extension phase, receiving GlyphAllo for an additional six weeks. The BUOY-1 study builds on successful phase 1 and phase 2a data and will assess the efficacy, safety and tolerability of GlyphAllo in up to 360 adults over six weeks.